Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors

Neoplasia (United States)

Volumn 17, Issue 9, 2015, Pages 735-741

  Bondarenko, Gennadiy ^a,b   Ugolkov, Andrey ^a,b   Rohan, Stephen ^a   Kulesza, Piotr ^a   Dubrovskyi, Oleksii ^a,b   Gursel, Demirkan ^a   Mathews, Jeremy ^a   O'Halloran, Thomas V ^b   Wei, Jian J ^a   Mazar, Andrew P ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD45 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BLADDER CANCER; BREAST CANCER; CANCER GRAFT; CANCER GROWTH; CANCER INFILTRATION; CANCER MORPHOLOGY; CANCER PATIENT; CANCER SUSCEPTIBILITY; CANCER TRANSPLANTATION; COLON CANCER; DISTANT METASTASIS; EPSTEIN BARR VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; KIDNEY CANCER; LIVER; LIVER METASTASIS; LUNG; LUNG METASTASIS; LYMPH NODE; LYMPH NODE METASTASIS; LYMPHOCYTE; LYMPHOMA; MONONUCLEAR CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETRANSPLANTATION; SPLEEN; T LYMPHOCYTE; TUMOR ENGRAFTMENT; TUMOR XENOGRAFT; ANIMAL; DRUG SCREENING; IMMUNOLOGY; PATHOLOGY; PROCEDURES; XENOGRAFT;

ANIMALS; B-LYMPHOCYTES; HUMANS; LYMPHOMA; MICE; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84948992756     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2015.09.004     Document Type: Article

References (24)

1. Richmond A and Su Y (2008).Mouse xenograft models vs GEM models for human cancer therapeutics.Dis Model Mech 1, 78-82.http://dx.doi.org/10.1242/dmm.000976
2. SiolasDand HannonGJ (2013).Patient-derived tumor xenografts: Transforming clinical samples into mouse models.Cancer res 73, 5315-5319. http://dx.doi.org/10.1158/0008-5472.CAN-13-1069
3. Scott CL, Becker MA, Haluska P, and Samimi G (2013).Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment.Front oncol 3, 295.http://dx.doi.org/10.3389/fonc.2013.00295
4. Hidalgo M, Amant F, Biankin AV, Budinsk á E,Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, and M ælandsmo GM, et al (2014).Patient-derived xenograft models: An emerging platform for translational cancer research.Cancer discov 4(9), 998-1013
5. Rygaard J and Povlsen CO (1969).Heterotransplantation of a human malignant tumour to " nude " mice.Acta pathol microbiol scand 77(4),758-760
6. HoffmanRM(2010).Orthotopicmouse models expressing fluorescent proteins for cancer drug discovery.Expert opin drug discov 5(9), 851-866. http://dx.doi.org/10.1517/17460441.2010.510129
7. Lindberg JM, Newhook TE, Adair SJ, Walters DM, Kim AJ, Stelow EB, Parsons JT, and Bauer TW (2014).Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.Neoplasia 16(7), 562-571. http://dx.doi.org/10.1016/j.neo.2014.06.004.
8. Mattie M, Christensen A, Chang MS, Yeh W, Said S, Shostak Y, Capo L, Verlinsky A, An Z, and Joseph I, et al (2013). Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics.Neoplasia 15(10), 1138-1150
9. Diebel KW, Oko LM, Medina EM, Niemeyer BF, Warren CJ, Claypool DJ, Tibbetts SA, Cool CD, Clambey ET, and van Dyk LF (2015).Gammaherpesvirus small noncoding RNAs are bifunctional elements that regulate infection and contribute to virulence in vivo.MBio 6, e01670-14. http://dx.doi.org/10.1128/mBio.01670-14
10. Hillen KM, Gather R, Enders A, Pircher H, Aichele P, Fisch P, Blumenthal B, Schamel WW, Straub T, and Goodnow CC, et al (2015).T cell expansion is the limiting factor of virus control in mice with attenuated TCR signaling: Implications for human immunodeficiency.J immunol 194, 2725-2734. http://dx.doi.org/10.4049/jimmunol.1400328
11. Fujii E, Kato A, Chen YJ, Matsubara K, Ohnishi Y, and Suzuki M (2014).Characterization of EBV-related lymphoproliferative lesions arising in donor lymphocytes of transplanted human tumor tissues in the NOG mouse.Exp anim 63, 289-296
12. Chen K, Ahmed S, AdeyiO, Dick JE, and Ghanekar A (2012).Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus.Plos one 7, e39294. http://dx.doi.org/10.1371/journal.pone.0039294
13. Carbone A, Gloghini A, and Dotti G (2008).EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 13, 577-585. http://dx.doi.org/10.1634/theoncologist.2008-0036
14. Cohen JI, Mocarski ES, Raab-Traub N, Corey L, and Nabel GJ (2013).The need and challenges for development of an Epstein-Barr virus vaccine.Vaccine 31(SUPPL.2), B194-96. http://dx.doi.org/10.1016/j.vaccine.2012.09.041
15. Cohen JI, Kimura H, Nakamura S, Ko YH, and Jaffe ES (2009).Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: A status report and summary of an international meeting, 8-9 September 2008.Ann oncol 20, 1472-1482. http://dx.doi.org/10.1093/annonc/mdp064
16. Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, Jankowska-Gan E, Burlingham WJ, Sun X, and GulleyML, et al (2011). A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 85(1), 165-177. http://dx.doi.org/10.1128/JVI.01512-10
17. Kobayashi T, Owczarek TB, McKiernan JM, and Abate-Shen C (2015).Modelling bladder cancer in mice: opportunities and challenges.Nat Rev Cancer 15, 42-54. http://dx.doi.org/10.1038/nrc3858
18. Thorley-Lawson DA and Gross A (2004).Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350, 1328-1337
19. Stockmann C, Schadendorf D, Klose R, and Helfrich I (2014). The impact of the immune system on tumor: Angiogenesis and vascular remodeling.Front oncol 4, 69. http://dx.doi.org/10.3389/fonc.2014.00069.eCollection2014
20. Von Bonin M, Wermke M, Cosgun KN, Thiede C, Bornhauser M, and Wagemaker G, et al (2013).In vivo expansion of co-transplanted T cells impacts on tumor re-initiating activity of human acute myeloid leukemia in NSG mice.Plos one 8, e60680. http://dx.doi.org/10.1371/journal.pone.0060680
21. Ali N, Flutter B, SanchezRodriguez R, Sharif-Paghaleh E, Barber LD, Lombardi G, and Nestle FO (2012).Xenogeneic graft-versus-host-disease in nod-scid il-2r?null mice display a t-effector memory phenotype.PLoS One 7, e44219. http://dx.doi.org/10.1371/journal.pone.0044219
22. Covassin L, Laning J, Abdi R, LangevinDL, PhillipsNE, Shultz LD, and BrehmMA (2011).Human peripheral blood CD4 t cell-engrafted non-obese diabetic-scid il2r?(null) h2-ab1 (tm1gru) tg (human leucocyte antigen d-related 4) mice: A mouse model of human allogeneic graft-versus-host disease.Clin exp immunol 166, 269-280. http://dx.doi.org/10.1111/j.1365-2249.2011.04462.x
23. Gregoire-Gauthier J, Durrieu L, Duval A, Fontaine F, Dieng MM, Bourgey M, Patey-Mariaud de Serre N, Louis I, and Haddad E (2012).Use of immunoglobulins in the prevention of gvhd in a xenogeneic NOD/SCID/?cmouse model.Bone marrow transplant 47, 439-450. http://dx.doi.org/10.1038/bmt.2011.93
24. Laing ST, Griffey SM, Moreno ME, and Stoddart CA (2015).CD8-positive lymphocytes in graft-versus-host disease of humanized NOD.Cg-prkdc (scid)Il2rg(tm1Wjl)/SzJ mice.J Comp Pathol 152, 238-242. http://dx.doi.org/10.1016/j.jcpa.2014.12.010